BMP7 and neoplasm: TGF‐β stimulates the conversion of endothelial cells into CAFs, while bone morphogenic protein 7 (BMP7) maintains the endothelial fate,15 indicating that antiangiogenic treatment of tumours, such as TGF‐β inhibitors or BMP7 agonists, may function as potential targets for decreasing activated fibroblasts.